APUS (STOCKS)
Apimeds Pharmaceuticals US, Inc.
$4.620000
-0.080000 (-1.70%)
Prev close: $4.700000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Sungjoon Chae; Vinod Menon, PhD
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5.72M
- Employees
- 2
- P/E (TTM)
- -0.17
- P/B (TTM)
- 0.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$16.92M |
| Operating Expenses | $23.73M |
| Research and Development | $2.53M |
| Other Operating Expenses | $21.20M |
| Operating Income/Loss | -$23.73M |
| Income/Loss From Continuing Operations After Tax | -$40.66M |
| Income/Loss From Continuing Operations Before Tax | -$40.66M |
| Net Income/Loss | -$40.66M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$40.66M |
| Net Income/Loss Available To Common Stockholders, Basic | -$40.66M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.74 |
| Diluted Earnings Per Share | -$2.74 |
| Basic Average Shares | 39,031,495 |
| Diluted Average Shares | 39,031,495 |
| Assets | $141.22M |
| Current Assets | $13.15M |
| Prepaid Expenses | $2.63M |
| Other Current Assets | $10.53M |
| Noncurrent Assets | $128.07M |
| Fixed Assets | $56.59K |
| Non-current Prepaid Expenses | $22.41K |
| Other Non-current Assets | $127.99M |
| Liabilities | $14.70M |
| Current Liabilities | $14.58M |
| Noncurrent Liabilities | $118.82K |
| Equity | $126.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $126.52M |
| Liabilities And Equity | $141.22M |
| Net Cash Flow From Operating Activities | -$10.97M |
| Net Cash Flow From Operating Activities, Continuing | -$10.97M |
| Net Cash Flow From Investing Activities | -$9.32M |
| Net Cash Flow From Investing Activities, Continuing | -$9.32M |
| Net Cash Flow From Financing Activities | $21.27M |
| Net Cash Flow From Financing Activities, Continuing | $21.27M |
| Net Cash Flow | $976.08K |
| Net Cash Flow, Continuing | $976.08K |
| Comprehensive Income/Loss | -$40.66M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$40.66M |
| Other Comprehensive Income/Loss | $0.00 |